Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Ontology highlight
ABSTRACT: Esophageal cancer is the seventh most common cancer worldwide and continues to have a poor prognosis. Starting with the development of immune checkpoint inhibitors for patients with metastatic melanoma, many clinical trials have been conducted to evaluate the efficacy and safety of immune checkpoint inhibitors against various malignancies. Although few effective drugs are available for patients with advanced esophageal cancer, two immune checkpoint inhibitors, nivolumab and pembrolizumab, have been approved as second-line treatments for advanced esophageal squamous cell carcinoma. Recently, immune checkpoint inhibitors have shown promising results as post-operative therapies and first-line treatments for advanced esophageal cancer. Nivolumab has been approved as a post-operative therapy ba
SUBMITTER: Kadono T
PROVIDER: S-EPMC9538995 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA